TREACE MEDICAL CONCEPTS, INC.
About TREACE MEDICAL CONCEPTS, INC.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $212.7M
- Net income
- -$59.0M
- Total assets
- $190.6M
- Market cap
- $227.7M
- Gross margin
- 79.8%
- Operating margin
- -25.5%
- Net margin
- -27.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $212.7M
- Cost of revenue
- $42.9M
- Gross profit
- $169.8M
- Operating expenses
- $223.9M
- Operating income
- -$54.2M
- Income tax
- $0
- Net income
- -$59.0M
- EPS (basic)
- $-0.93
- EPS (diluted)
- $-0.93
Balance sheet
- Total assets
- $190.6M
- Current assets
- $132.1M
- Total liabilities
- $103.2M
- Current liabilities
- $30.6M
- Shareholders’ equity
- $87.3M
Cash flow
- Operating cash flow
- -$16.0M
- Investing cash flow
- $13.3M
- Financing cash flow
- $2.1M
- Net cash flow
- -$642.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $227.7M
- EPS (diluted)
- $-0.93
- Shares outstanding
- 64.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 23, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $59.0M in FY2025.
- Revenue grew 125% from FY2021 to FY2025.
- Gross margin of 79.8%, net margin -27.7%.
- Trading 54% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TREACE MEDICAL CONCEPTS, INC..
Write a review
News about TREACE MEDICAL CONCEPTS, INC.
News & sentiment via Polygon.io
